Department of Angiology, Center of Vascular Medicine "Oberrhein" Speyer, Diakonissen-Stiftungs-Krankenhaus, Speyer; Department of Diabetology and Angiology, Marienkrankenhaus, Soest; Department of Angiology, University Hospital Leipzig; Department of Angiology, Department of Medicine 1, University Hospital Mannheim.
Dtsch Arztebl Int. 2020 Mar 13;117(11):188-193. doi: 10.3238/arztebl.2020.0188.
The conservative treatment of peripheral arterial disease (PAD), as recommended in current guidelines, encompasses measures such as lifestyle modification and risk-factor management. In addition, in patients with vasogenic intermittent claudication (IC), it is recommended that patients first be given drugs to improve perfusion and undergo supervised gait training. Revascularization is not recommended for asymptomatic persons, but it is considered mandatory for patients with critical ischemia. In this article on conservative and revascularizing treatment strategies for IC, we address the following questions: whether all treatment options are available, how effective they are, and whether the reality of treatment for IC in Germany corresponds to what is recommended in the guidelines.
In 2014, the German Society for Angiology carried out a comprehensive literature search in order to prepare a new version of the S3 guideline on PAD. This literature search was updated up to 2018, with identical methods, for the present review.
The benefit of lifestyle modification and risk factor treatment is supported by high-level evidence ( evidence level I, recommendation grade A ). The distance patients are able to walk without pain is increased by drug therapy as well (evidence level IIb), but the therapeutic effect is only moderate. Supervised exercise training (SET), though supported by high-level evidence (I, A), is of limited efficacy, availability, and applicability, and patient compliance with it is also limited. In patients with IC, revascularization leads to complete relief of symptoms more rapidly than gait training, and its long-term benefit is steadily improving owing to advances in medical technology. A combination of arterial revascularization and gait training yields the best results. In a clinical trial, patients with IC who underwent combined therapy increased the distance they could walk without pain by 954 m in six months, compared to 407 m in a group that underwent gait training alone.
In the treatment of vasogenic IC, SET and drugs to increase perfusion are now giving way to revascularization, which is more effective. As far as can be determined, SET is not currently implemented at all in the German health care system. It would be desirable for SET to be more available and more widely used, both to sustain the benefit of revascularization over the long term and to lower the general cardiovascular risk.
目前的指南建议对外周动脉疾病 (PAD) 进行保守治疗,包括生活方式改变和危险因素管理等措施。此外,对于血管性间歇性跛行 (IC) 患者,建议首先给予改善灌注的药物,并进行监督下的步行训练。对于无症状患者不建议进行血运重建,但对于严重缺血患者则认为是必需的。在这篇关于 IC 的保守和血运重建治疗策略的文章中,我们将讨论以下问题:是否提供了所有的治疗选择、它们的疗效如何,以及德国 IC 的治疗现状是否符合指南的建议。
2014 年,德国血管外科学会进行了全面的文献检索,以便为 PAD 的 S3 指南制定新版本。本综述使用了相同的方法,对 2018 年之前的文献检索进行了更新。
生活方式改变和危险因素治疗的益处得到了高级别证据的支持(证据水平 I,推荐等级 A)。药物治疗也能增加患者的无痛行走距离(证据水平 IIb),但治疗效果只是中等。监督下的运动训练(SET)虽然得到了高级别证据的支持(I,A),但其疗效、可及性和适用性有限,患者的依从性也有限。对于 IC 患者,血管重建比步行训练更快地缓解症状,并且由于医疗技术的进步,其长期获益不断提高。动脉血运重建和步行训练的联合治疗效果最佳。在一项临床试验中,接受联合治疗的 IC 患者在六个月内无痛行走距离增加了 954 米,而单独接受步行训练的患者仅增加了 407 米。
在血管性 IC 的治疗中,SET 和增加灌注的药物现在正在让位于更有效的血运重建。据确定,SET 在德国卫生保健系统中目前根本没有得到实施。希望 SET 更广泛地应用,以维持血运重建的长期获益,并降低总体心血管风险。